Alnylam Pharmace. buy StockNews.com
Start price
27.12.24
/
50%
€230.70
Target price
27.12.25
-
Performance (%)
46.25%
End price
28.12.25
€337.40
Summary
This prediction ended on 28.12.25 with a price of €337.40. The BUY prediction by StockNews_com for Alnylam Pharmace. saw massive gains of 46.25%. StockNews_com has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. StockNews_com has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | -0.982% | -0.982% | -10.108% |
| iShares Core DAX® | 1,35 % | 2,74 % | 7,87 % |
| iShares Nasdaq 100 | 3,28 % | 6,51 % | 41,46 % |
| iShares Nikkei 225® | 7,43 % | 17,83 % | 69,10 % |
| iShares S&P 500 | 1,70 % | 3,10 % | 27,31 % |
Comments by StockNews_com for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von StockNews_com gewählte maximale Laufzeit wurde überschritten